HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

NCT01494662 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: HKI-272
PROCEDURE: Surgical Resection
DRUG: Capecitabine
DRUG: HKI-272
DRUG: Ado-Trastuzumab Emtansine

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]